As part of the agreement, MD Anderson is eligible to receive certain payments based on the future development of BLU-222. MD Anderson and Blueprint Medicines will jointly design translational studies, and Blueprint Medicines will provide funding, research compounds and additional support. TRACTION is a core component of MD Anderson's Therapeutics Discovery division, an integrated team of clinicians, researchers and drug development experts working to advance impactful therapies that address patient needs. Under the preclinical collaboration agreement, Blueprint Medicines expects to collaborate primarily with MD Anderson's Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, which leads cutting-edge translational biology research to rapidly position new therapies for clinical trials. "By leveraging the power of MD Anderson's expertise in translational research, we aim to reveal the broad potential of BLU-222 and optimize our clinical development strategy to bring treatment innovation to as many patients as possible." "This collaboration highlights our commitment to rapidly advance innovative science and builds on our prior efforts – also supported by MD Anderson investigators – that led to two FDA-approved and breakthrough therapy-designated precision therapies for patients with cancer," said Fouad Namouni, M.D., President of Research and Development at Blueprint Medicines. The teams seek to characterize the range of cancer types susceptible to treatment with a selective CDK2 inhibitor, advance BLU-222 mono- and combination-therapy strategies with the potential to maximize patient benefit, and identify novel biomarkers that may better predict treatment response and optimize patient selection. The collaboration brings together MD Anderson translational research scientists, the drug development capabilities of MD Anderson's Therapeutics Discovery division and Blueprint Medicines' precision therapy pipeline and expertise.
0 kommentar(er)
